Four drug firms are fined £3.4m for fixing price of nortriptyline
BMJ 2020; 368 doi: https://doi.org/10.1136/bmj.m925 (Published 05 March 2020) Cite this as: BMJ 2020;368:m925
- Clare Dyer
- The BMJ
Four drug companies have been fined a total of £3.4m (€3.9m; $4.4m) for illegal information sharing and illegally carving up the market for an antidepressant used by thousands of NHS patients every day. After an investigation by the Competition and Markets Authority (CMA), the NHS will also receive a direct payment of £1m from two of the companies—only the second time this has happened as a result of a CMA probe.
The investigation found that King Pharmaceuticals and Auden Mckenzie colluded to share the market and fix quantities and prices in …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.